



ASX ANNOUNCEMENT

20 October 2008

Results of second patient treated with VitroGro®

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** today announced the results of the second patient treated with VitroGro®, as summarised in the attached update.

The second patient was a 72-year-old male who had suffered for six months with two adjacent venous ulcers on his left ankle, which had not healed with compression bandaging applied by the patient at home. Treatment with VitroGro® occurred twice weekly with compression bandaging and ceased after 15 days. The treatment resulted in a 75 per cent total reduction in ulcer area after 24 days. As with the first patient, Mrs Dot Harrison, there was also a marked improvement in the health of the tissue at the edge of the second patient's ulcers.

Since the announcement of Mrs Harrison's results at the end of her trial period (**ASX: TIS 3 Sep 2008**), the ulcer treated with VitroGro® has completely healed and it is expected that the ulcers of the second patient will also heal completely in the near future. In both the first and second patients, there were no adverse reactions.

Tissue Therapies CEO, Dr Steven Mercer, said the Tissue Therapies team was delighted with the results.

"The results from the first two patients have shown an exceptional rate of healing and improvement in tissue health at the ulcer edges.

"These results are certainly consistent with our understanding of the how VitroGro® works and we are looking forward to the rest of the clinical results with even greater anticipation.

"We are delighted that the first patient's ulcer has now healed and anticipate that the ulcers of the second patient will do the same."

Further information:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: 07 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic ulcers and burns,

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com

